Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Vancomycin-traditional dosing

PreclinicalSmall molecule

HHamad Medical Corporation

Vancomycin-traditional dosing is one of 2 small molecule programs targeting Drug Monitoring. It is currently in Preclinical.

1

Indications

1

Total Trials

0

Active Trials

1

Competitors

Pipeline

Status by Indication[3][1]

Indication

Drug MonitoringCompleted

Drug MonitoringPreclinical

Completed

Competition

Competitive Landscape

1 competitor in Drug Monitoring

#DrugCompanyPhaseTrials

Vfend

PPrism Pharmaceuticals

Vancomycin-traditional dosing

HHamad Medical Corporation

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Drug Monitoring1 trial

Economic Evaluation of Vancomycin Therapeutic Drug Monitoring Methods

Completed·HHamad Medical Corporation·N/A·NCT04297176·65 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Vancomycin-traditional dosing. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Vancomycin-traditional dosing compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Vancomycin-traditional dosing. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hamad Medical Corporation company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: HHamad Medical Corporation

Related News